Protein– tag –
-
FDA Grants Accelerated Approval to Regeneron’s Bispecific Antibody Linvoseltamab (LYNOZYFIC) for Multiple Myeloma
International Myeloma Foundation USA Overview The International Myeloma Foundation reported that LYNOZYFIC (linvoseltamab-gcpt), a BCMA-CD3 bispecific antibody immunotherapy, received accelerated FDA approval in July 2025. This drug targ... -
ARNT Molecular Glue Degrader NEO-811 Initiates Phase 1/2 First-in-Human Study for Unresectable Clear Cell Renal Cell Carcinoma
Medical Oncology and Hematology Global Overview The NEO-811-101 study has commenced as an open-label, first-in-human, Phase 1/2 dose-escalation and expansion study of the ARNT molecular glue degrader, NEO-811. Targeting patients with loc... -
Bambusa Therapeutics’ Bispecific Antibody BBT001 Achieves Rapid, Durable Itch Relief and AD Improvement in Phase 1 Atopic Dermatitis Trial
Dermatology Times USA Overview Preliminary Phase 1 clinical data for Bambusa Therapeutics' bispecific antibody BBT001 shows rapid and sustained improvement in disease severity and pruritus in moderate-to-severe atopic dermatitis (AD) pat... -
Dove Medical Press Reviews Exosome-Inspired Nanocarriers: Next-Gen Drug Delivery for Cancer Therapy
Dove Medical Press UK Overview Dove Medical Press published a review on exosomes as next-generation bio-derived drug delivery systems for cancer therapy. The review emphasizes exosomes' natural ability to cross biological barriers and th... -
Beyond Vaccines: mRNA Technology Expands into Personalized Cancer, Protein Replacement, and Regenerative Medicine
Unknown Global Overview mRNA technology is rapidly expanding beyond vaccines into new medical applications, including personalized cancer vaccines, protein replacement therapies, and regenerative medicine. Ongoing research is actively fo... -
Self-Amplifying RNA (saRNA) Gains Ground Over Conventional mRNA, Proving Superiority Across Diverse Therapeutics; First COVID-19 Vaccines Approved in Japan and EU
TriLink BioTechnologies USA Overview Self-amplifying RNA (saRNA) is gaining traction over conventional mRNA due to its ability to amplify transcripts inside cells, producing more protein per molecule and sustaining expression for days to... -
EMA Recommends Approval for New Hypercholesterolemia Drug Evlarco (Obicetrapib / Ezetimibe): A Combination of CETP Inhibitor and Cholesterol Absorption Inhibitor
EMA EU Overview On July 23, 2026, the EMA's CHMP adopted a positive opinion recommending marketing authorization for Evlarco (obicetrapib / ezetimibe). This oral medication is for the treatment of primary hypercholesterolemia or mixed dy... -
PROTAC Research Shifts to Structural Design, Oral Bioavailability, and AI-Driven Approaches: Bibliometric Analysis Reveals Emerging Frontiers and Pivotal Trial Era
PubMed USA Overview A bibliometric analysis of 2,630 PROTAC publications from 2001-2025 reveals a shift from early E3 ligase recruitment research to current hotspots including structural basis, ternary complex design, EGFR-directed degra... -
FDA Approval of First PROTAC Vepdegestrant Raises New Challenges in Targeted Protein Degradation Patent Strategy
Elkington and Fife UK Overview The FDA approval of vepdegestrant, the first PROTAC, marks a significant milestone for targeted protein degradation (TPD), bringing complex intellectual property considerations to the forefront. The unique ... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut...
